Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12780598 | 0.90 | CHRNB2 (0.42) | PRKCACHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL21098352 | 0.86 | PRKCA (0.40) | PRKCAPRKCEPRKCQPRKCDCHRNB2 | |
| SCHEMBL12199642 | 0.85 | MAPK1 (0.41) | PRKCAPRKCEPRKCQPRKCDCHRNB2 | |
| SCHEMBL18650144 | 0.84 | CYP1A2 (0.42) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL22420232 | 0.83 | PRKCA (0.40) | PRKCAPRKCEPRKCQPRKCDCHRNB2 | |
| SCHEMBL24073589 | 0.81 | CHRNB2 (0.36) | PRKCACHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL9671738 | 0.80 | PRKCA (0.50) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL14193886 | 0.79 | EPHX1 (0.42) | PRKCAPRKCEPRKCQPRKCDCHRNB2 | |
| SCHEMBL19435389 | 0.79 | CTSK (0.39) | PRKCAPRKCEPRKCQPRKCDCHRNB2 | |
| SCHEMBL12315113 | 0.77 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144833-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144865-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-05-12 | — | — | US | disclosed |
| US-20220119428-A1 | PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-04-21 | — | — | US | disclosed |
| US-11248012-B2 | Phospholipidation of imidazoquinolines and oxoadenines | GLAXO SMIIHKLINE BIOLOGICALS SA (BE) | 2022-02-15 | — | — | US | disclosed |
| US-20210277038-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2021-09-09 | — | — | US | disclosed |
| US-20210024553-A1 | PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2021-01-28 | — | — | US | disclosed |
| WO-2018046460-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277038-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | MAVS, IRF3, MYD88 | PRKCA 2914/4885PRKCE 2921/4885PRKCQ 712/4885 |
| US-20220144865-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | MAVS, IRF3, MYD88 | PRKCA 2914/4885PRKCE 2921/4885PRKCQ 712/4885 |
| US-20220144833-A1 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | MAVS, IRF3, MYD88 | PRKCA 2914/4885PRKCE 2921/4885PRKCQ 712/4885 |
| US-20210024553-A1 | PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINES | TLR7, TLR8, TLR9 | PRKCA 1778/4885PRKCE 2094/4885PRKCQ 978/4885 |
| US-20220119428-A1 | PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINES | TLR7, TLR8, TLR9 | PRKCA 1732/4885PRKCE 2031/4885PRKCQ 968/4885 |
| US-11248012-B2 | Phospholipidation of imidazoquinolines and oxoadenines | TLR7, TLR8, TLR9 | PRKCA 1778/4885PRKCE 2094/4885PRKCQ 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.